Enveric Unveils Positive Results From Preclinical Studies Supporting Metabolic Profile Of Its Psilocin Prodrug For Anxiety
Portfolio Pulse from Vuk Zdinjak
Enveric Biosciences (NASDAQ:ENVB) has announced successful completion of preclinical absorption, distribution, metabolism, and excretion (ADME) and toxicology studies for its lead candidate EB-373. The studies support the company's clinical design objectives for reduced side effects and shorter duration of hallucinatory effect. The in vitro assays demonstrated efficient conversion of EB-373 to active metabolite psilocin, with consistent results across all species. The company is increasingly confident that EB-373 has the potential to be well tolerated with an improved side effect profile.
July 24, 2023 | 12:57 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Enveric Biosciences has announced positive preclinical results for its lead candidate EB-373, which could potentially lead to an improved therapeutic option for patients. This could positively impact the company's stock.
The positive preclinical results for Enveric Biosciences' lead candidate EB-373 indicate that the company is making progress in its research and development efforts. This could potentially lead to an improved therapeutic option for patients, which could increase the company's market share and revenue, thereby positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100